An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.70117
Abstract: A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates,… read more here.
Keywords: potential encorafenib; drug interaction; drug; cocktail ... See more keywords
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01627-8
Abstract: Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. However,… read more here.
Keywords: braf v600e; cetuximab; cost effectiveness; cost ... See more keywords
BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer letters"
DOI: 10.1016/j.canlet.2020.11.036
Abstract: BRAFV600- and MEK1/2-targeting therapies rarely produce durable response in melanoma patients. We investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib (Braftovi), a recently FDA-approved BRAFV600… read more here.
Keywords: brafv600e melanoma; apoptosis; bcl; cell ... See more keywords
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.07.016
Abstract: BACKGROUND Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on… read more here.
Keywords: adverse events; encorafenib; columbus study; encorafenib binimetinib ... See more keywords
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02659
Abstract: PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we… read more here.
Keywords: year; braf v600; encorafenib; v600 mutant ... See more keywords
Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor
Sign Up to like & getrecommendations! Published in 2024 at "Oncotarget"
DOI: 10.18632/oncotarget.28654
Abstract: Glomus tumors (GT) are very rare mesenchymal neoplasms arising from glomus bodies, arteriovenous structures located in the dermis and involved in thermoregulation. Although most are benign, they may occasionally present malignant histological features associated with… read more here.
Keywords: encorafenib; braf v600e; response; glomus ... See more keywords